CSL Ltd Asset Resilience Ratio
CSL Ltd asset resilience ratio. CSL Ltd (CSL) has an Asset Resilience Ratio of 0.41% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of CSL Ltd for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of CSL Ltd (1997–2023)
Asset resilience ratio of CSL Ltd from 1997 to 2023. This chart shows how CSL Ltd's Asset Resilience Ratio has changed over time. See cash generation quality of CSL Ltd to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down CSL Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is CSL Ltd's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$157.48 Million | 0.41% |
| Total Liquid Assets | AU$157.48 Million | 0.41% |
Asset Resilience Insights
- Limited Liquidity: CSL Ltd maintains only 0.41% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
CSL Ltd Industry Peers by Asset Resilience Ratio
Compare CSL Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
CSL Ltd Asset Resilience Ratio by Year (1997–2023)
CSL Ltd asset resilience ratio by year from 1997 to 2023. The table below shows the annual Asset Resilience Ratio data for CSL Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-06-30 | 0.02% | AU$9.00 Million ≈ $6.37 Million |
AU$54.43 Billion ≈ $38.52 Billion |
+0.01pp |
| 2022-06-30 | 0.01% | AU$4.20 Million ≈ $2.97 Million |
AU$41.22 Billion ≈ $29.17 Billion |
-0.01pp |
| 2021-06-30 | 0.02% | AU$3.60 Million ≈ $2.55 Million |
AU$18.16 Billion ≈ $12.85 Billion |
0.00pp |
| 2020-06-30 | 0.02% | AU$3.30 Million ≈ $2.33 Million |
AU$15.46 Billion ≈ $10.94 Billion |
+0.02pp |
| 2019-06-30 | 0.00% | AU$279.62K ≈ $197.85K |
AU$12.27 Billion ≈ $8.68 Billion |
-0.01pp |
| 2018-06-30 | 0.01% | AU$1.18 Million ≈ $833.32K |
AU$10.73 Billion ≈ $7.60 Billion |
-0.05pp |
| 2017-06-30 | 0.06% | AU$5.20 Million ≈ $3.68 Million |
AU$9.12 Billion ≈ $6.45 Billion |
+0.05pp |
| 2016-06-30 | 0.01% | AU$601.19K ≈ $425.38K |
AU$7.58 Billion ≈ $5.36 Billion |
-0.03pp |
| 2015-06-30 | 0.04% | AU$1.98 Million ≈ $1.40 Million |
AU$4.87 Billion ≈ $3.44 Billion |
+0.04pp |
| 2014-06-30 | 0.00% | AU$300.00K ≈ $212.27K |
AU$6.28 Billion ≈ $4.44 Billion |
0.00pp |
| 2013-06-30 | 0.01% | AU$500.00K ≈ $353.78K |
AU$5.98 Billion ≈ $4.23 Billion |
-0.02pp |
| 2012-06-30 | 0.03% | AU$1.86 Million ≈ $1.32 Million |
AU$6.03 Billion ≈ $4.26 Billion |
-0.32pp |
| 2011-06-30 | 0.36% | AU$20.57 Million ≈ $14.55 Million |
AU$5.79 Billion ≈ $4.10 Billion |
+0.35pp |
| 2010-06-30 | 0.01% | AU$343.08K ≈ $242.75K |
AU$4.09 Billion ≈ $2.89 Billion |
0.00pp |
| 2009-06-30 | 0.01% | AU$550.99K ≈ $389.86K |
AU$4.75 Billion ≈ $3.36 Billion |
-0.02pp |
| 2008-06-30 | 0.03% | AU$1.45 Million ≈ $1.02 Million |
AU$4.49 Billion ≈ $3.18 Billion |
+0.02pp |
| 2007-06-30 | 0.01% | AU$426.98K ≈ $302.12K |
AU$3.02 Billion ≈ $2.14 Billion |
-0.17pp |
| 2006-06-30 | 0.19% | AU$4.31 Million ≈ $3.05 Million |
AU$2.29 Billion ≈ $1.62 Billion |
-4.46pp |
| 2002-06-30 | 4.64% | AU$60.45 Million ≈ $42.77 Million |
AU$1.30 Billion ≈ $921.05 Million |
-8.45pp |
| 2001-06-30 | 13.10% | AU$60.87 Million ≈ $43.07 Million |
AU$464.77 Million ≈ $328.86 Million |
-30.45pp |
| 2000-06-30 | 43.54% | AU$147.68 Million ≈ $104.49 Million |
AU$339.16 Million ≈ $239.98 Million |
+35.94pp |
| 1999-06-30 | 7.60% | AU$18.95 Million ≈ $13.41 Million |
AU$249.27 Million ≈ $176.37 Million |
+0.12pp |
| 1998-06-30 | 7.48% | AU$15.01 Million ≈ $10.62 Million |
AU$200.68 Million ≈ $142.00 Million |
-0.88pp |
| 1997-06-30 | 8.36% | AU$32.21 Million ≈ $22.79 Million |
AU$385.18 Million ≈ $272.54 Million |
-- |
About CSL Ltd
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma produ… Read more